Topical SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, lowers intraocular pressure in conscious rabbits.

Abstract

This investigation was carried out to evaluate the effect of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, on intraocular pressure (IOP) in rabbits. A randomized, placebo-controlled, double-masked, crossover study with topical application of SDZ GLC-756 eyedrops [0.015% (n = 10), 0.03% (n = 10), 0.0625% (n = 10), 0.125% (n = 9), 0.25% (n = 10), 0.5% (n = 14)] and vehicle alone (placebo-control) to the right eye was performed in New Zealand White rabbits. The contralateral eye received no treatment. IOP was measured using a pneumatonometer. Topical SDZ GLC-756 significantly lowered IOP in a dose-dependent manner (maximal IOP-lowering effect 1 approximately 2 hours after administration) in the treated eye and, to a lesser extent, in the contralateral eye. The duration of action was approximately 4 hours. The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacological approach to the treatment of glaucoma, which deserves further investigation.

• Authors: C Prünte, I Nuttli, R Markstein
• Journal: Japanese journal of ophthalmology (Jpn J Ophthalmol) Vol. 40 Issue 2 Pg. 167-73 ( 1996) ISSN: 0021-5155 [Print] Japan
• PMID: 8876383 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Ophthalmic Solutions
• Quinolines
• Receptors, Dopamine D1
• Receptors, Dopamine D2
• SDZ GLC 756

Topics

• Administration, Topical
• Animals
• Consciousness
• Cross-Over Studies
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Intraocular Pressure (drug effects)
• Male
• Ocular Hypotension (chemically induced)
• Ophthalmic Solutions
• Quinolines (administration & dosage)
• Rabbits
• Receptors, Dopamine D1 (antagonists & inhibitors)
• Receptors, Dopamine D2 (agonists)
• Tonometry, Ocular